$IBRX continues higher after reporting preliminary 400% sales growth for ANTIKVA.
This can go mu...
Twitter
Note: AI-generated summary based on third-party content. Not financial advice. Read more.
Quick Insights
Immunitybio Inc (IBRX) is experiencing significant upward momentum, trading at $3.40 USD, up 12.42% today, following preliminary reports of 400% sales growth for its product ANTIKVA. The author suggests this stock has substantial upside potential due to its perceived role as a "cure for cancer." Investors should note the high-risk nature of this investment as highlighted by the author's bio.
Ask about this postAnswers are grounded in this post's content.
Tweet
About Beanie
Beanie
By beaniemaxi
Crypto native since the early days. Went all in on DeFi summer. Then tripled down on NFTs. VC @gmcapital_. No paid promos. Not financial advice. I talk my book.